{"filings":[{"id":90615,"accession_number":"0001437749-26-015928","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.","Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.","Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).","Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":34076000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90614,"accession_number":"0001437749-26-012368","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["9.01","8.01"],"status":"ready","headline":"Integrated BioPharma receives 3-month extension of PNC line of credit to July 14, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["PNC Bank notified Integrated BioPharma and subsidiary Manhattan Drug on April 14, 2026.","Line of credit expiration extended from April 15, 2026 to July 14, 2026.","Extension subject to PNC's sole discretion to designate a later date via written notice.","No changes to other terms of the promissory note dated April 15, 2025 were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100290,"accession_number":"0001437749-26-004553","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Integrated Biopharma subsidiary amends lease with related party; rent increases to $1.1M/yr through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manhattan Drug subsidiary reduced leased space from 116,175 to 110,095 sq ft at Hillside, NJ facility.","Annual base rent increased from $845,966 to $1,100,950 (3% annual escalator); lease extended to Jan 31, 2029.","Lessor Vitamin Realty is 100% owned by estate of former chairman and by co-CEOs who are also directors (related party).","Tenant also pays proportionate share of operating expenses (70.12% of building).","All other terms of original lease remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100289,"accession_number":"0001437749-26-003808","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.","Net loss $0.8M vs net income $0.1M; diluted EPS $(0.03) vs $0.00.","Six-month revenue $24.0M vs $26.2M; operating loss $0.7M vs income $0.7M.","Two largest contract manufacturing customers accounted for ~89% of total revenue.","Selling and administrative expenses decreased slightly to $0.9M from $1.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":23969000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116621,"accession_number":"0001437749-25-036573","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders re-elect director, approve 3-year say-on-pay frequency, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eric Friedman re-elected as Class III director with 20.66M votes for, 183k withheld, and 1.81M broker non-votes.","Non-binding advisory vote: 20.40M shares favor 3-year frequency for executive compensation votes.","Executive compensation say-on-pay approved: 20.79M for, 56,978 against, 700 abstain.","Ratification of CBIZ CPAs P.C. as independent auditors for FY2026: 22.54M for, 113k against, 1,138 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116620,"accession_number":"0001437749-25-034091","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue down 6.6% to $12.7M; net income $0.1M, EPS $0.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.7M, down 6.6% from $13.6M YoY; gross profit $1.0M vs $1.4M.","Net income $123K ($0.00 basic EPS) vs $259K ($0.01) in prior year quarter.","Operating income $163K vs $490K YoY, driven by lower gross profit.","Two largest customers in Contract Manufacturing = 87% of total revenue (85% in prior year)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12689000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133073,"accession_number":"0001437749-25-029717","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.","Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.","FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.","FY operating income $2.0M vs $251k; selling and administrative expenses flat.","Weighted average diluted shares for FY 31.2M vs 30.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149656,"accession_number":"0001437749-25-016809","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).","Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.","Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.","Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.","Co-CEOs cite customer base expansion and revenue growth from core business."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":40178000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149655,"accession_number":"0001437749-25-012917","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Integrated BioPharma replaces auditor Marcum with CBIZ CPAs after Marcum's attest business acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as auditor effective April 24, 2025; CBIZ CPAs P.C. engaged for fiscal year ending June 30, 2025.","Marcum's reports for FY 2024 and 2023 were unqualified, with no adverse opinions or modifications.","No disagreements or reportable events between the Company and Marcum during the past two fiscal years and interim period.","No prior consultations with CBIZ CPAs regarding accounting principles, audit opinions, or reportable events.","Change approved by Audit Committee; Marcum provided a letter to the SEC agreeing with the disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149654,"accession_number":"0001437749-25-012475","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.02","1.01","2.03","9.01"],"status":"ready","headline":"Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).","Maturity date April 5, 2026; borrowed funds for working capital and equipment purchases.","Prior credit facility fully repaid and terminated; payoff amount was $7,864.51 on April 15, 2025.","Reimbursement agreement covers standby/commercial letters of credit up to $1M sublimit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168703,"accession_number":"0001437749-25-003765","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).","Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.","Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.","Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.","Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":26231000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185813,"accession_number":"0001437749-24-036441","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Integrated BioPharma elects two Class I directors, ratifies Marcum as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Damon DeSantis as Class I director: 20,448,871 for, 142,036 withheld, 1,342,353 broker non-votes.","Elected Riva Sheppard as Class I director: 20,301,671 for, 289,236 withheld, 1,342,353 broker non-votes.","Ratified appointment of Marcum LLP as independent auditor for FY2025: 21,905,273 for, 9,287 against, 18,700 abstain.","Total shares voted: 21,933,260 of 30,099,610 entitled; quorum present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185812,"accession_number":"0001437749-24-035331","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.","Net income $259K ($0.01 diluted EPS) compared to net loss of $59K ($0.00) in prior year.","Two largest customers represented 85% of revenue (down from 91%), reflecting diversification.","No forward guidance or dividend changes were provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":13617000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202382,"accession_number":"0001437749-24-029810","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).","Operating income improved to $402K Q4 and $251K FY, from $79K and $120K prior.","Net income Q4 $268K ($0.01 diluted) vs $40K ($0.00); FY net income $112K ($0.00) vs net loss $34K.","Two largest customers accounted for 90% of FY2024 revenue (89% prior year).","Co-CEOs cite focus on core businesses and new prospects to diversify customer base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218501,"accession_number":"0001437749-24-016041","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.","Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.","Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).","Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":37571000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}